Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: A phase III randomized, multicenter, double-blind clinical trial

International Journal of Infectious Diseases

Volumn 41, Issue , 2015, Pages 65-72

  Hartvickson, Robyn ^a   Cruz, Marilou ^b   Ervin, John ^c   Brandon, Donald ^d   Forleo Neto, Eduardo ^e   Dagnew, Alemnew F ^e   Chandra, Richa ^e   Lindert, Kelly ^e   Mateen, Ahmed Abdul ^f  

^a Heartland Research Associates   (United States)

^b Premier Health Research Center   (United States)

^c Center for Pharmaceutical Research   (United States)

^d California Research Foundation   (United States)

^e Novartis Vaccines and Diagnostics Inc   (United States)

^f Novartis Pharmaceuticals Canada Inc   (Canada)

Author keywords

Influenza; MDCK; Pediatric; Quadrivalent; Trivalent; Vaccine

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; ECCHYMOSIS; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; MAMMAL CELL; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SOMNOLENCE; VIRUS STRAIN; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; PRESCHOOL CHILD; VACCINATION;

ADOLESCENT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; SEROCONVERSION; VACCINATION; VACCINES, INACTIVATED;

EID: 84949197642     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.11.004     Document Type: Article

References (20)

1. World Health Organization. Influenza (seasonal). Geneva: WHO; Available at: (accessed June 8, 2014). http://www.who.int/mediacentre/factsheets/fs211/en/.
2. Glezen P., Denny F.W. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973, 288:498-505.
3. Longini I.M., Koopman J.S., Monto A.S., Fox J.P. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982, 115:736-751.
4. Glezen W.P., Couch R.B. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978, 298:587-592.
5. Fox J.P., Hall C.E., Cooney M.K., Foy H.M. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 1982, 116:212-227.
6. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:1-62.
7. Rota P.A., Wallis T.R., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. Co-circulation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990, 175:59-68.
8. US Centers for Disease Control and Prevention. Seasonal influenza activity surveillance reports: 1999-2000 to 2010-2011 seasons. Atlanta, GA: CDC; Available at: (accessed October 6, 2015). http://www.cdc.gov/flu/weekly/pastreports.htm.
9. World Health Organization. WHO/Europe influenza surveillance. Geneva: WHO; Available at: (accessed June 20, 2011). http://www.euroflu.org/index.php.
10. Ambrose C.S., Levin M.J. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012, 8:1-8.
11. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28:D45-D53.
12. Couch RB. Background and presentation of possible vaccine options. Vaccines and Related Biological Products Advisory Committee (VRBPAC), Food and Drug Administration, Topic 4: influenza type B strain - discussion on circulating lineages. 2007, USA.
13. Centers for Disease Control Prevention Influenza activity-United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep 2013, 62:473-479.
14. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30:1993-1998.
15. Gregersen J.P., Schmitt H.J., Trusheim H., Bröker M. Safety of MDCK cell culture-based influenza vaccines. Future Microbiol 2011, 6:143-152.
16. Katz J.M., Naeve C.W., Webster R.G. Host cell-mediated variation in H3N2 influenza viruses. Virology 1987, 156:386-395.
17. Katz J.M., Webster R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989, 160:191-198.
18. Meyer W.J., Wood J.M., Major D., Robertson J.S., Webster R.G., Katz J.M. Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology 1993, 196:130-137.
19. Fluzone quadrivalent influenza virus vaccine quadrivalent types A and B product monograph. 2014, Sanofi Pasteur Limited Toronto, Ontario, Canada. Available at: (accessed October 9, 2015). http://www.sanofipasteur.ca/sites/default/files/sites/default/files/pictures/450-FluzoneQIV-PM-E.pdf.
20. Vesikari T., Block S.L., Guerra F., Lattanzi M., Holmes S., Izu A., et al. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012, 31:494-500.